Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Observational, Multi-centred, Non-interventional Study on the Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia

NCT02827617 is registered in ClinicalTrials.gov with Oncology Institute of Southern Switzerland as lead sponsor.

NCT NCT02827617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02827617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Observational, Multi-centred, Non-interventional Study on the Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
Lead sponsor
Oncology Institute of Southern Switzerland
Phase
Observational
Overall status
Completed
Start date
June 1, 2016
Completion date
May 16, 2024
Enrollment
56 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia